Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

Tagged bpcia · clear

Patexia Insight 157: Most Active Companies in Biosimilar Litigation (BPCIA Act)

In late August, we published our third annual ANDA Litigation Intelligence Report. We evaluated the stakeholders for Hatch-Waxman cases filed between July 1, 2017, and June 30, 2022. This report's major highlights have been covered in our previous…

November 3, 2022Pharma & ANDA8 min read

Janssen and Celltrion: Remicade Biosimilar Patent Dance

Written by Daniel A. Kamkar and Agnes Juang, Ph.D. Janssen Biotech Inc. and Celltrion Healthcare have taken the next step over Janssen’s blockbuster arthritis biologic medicine Remicade (infliximab) and Celltrion’s biosimilar, as required by…

June 26, 2017Pharma & ANDA2 min read